Rapid and ultra-rapid insulin in glycemic control

Fast and ultra-fast insulin preparations are being currently developed and marketed in order to improve glycemic control in Type -1 Diabetes Mellitus (TIDM) patients, both in Continuous Subcutaneous Insulin Injection (CSII, insulin pump) and in traditional Multiple Daily Injection (MDI) therapy schemes. Ultra-fast insulins are reputed to allow better tailoring of blood-glucose reduction than currently available fast insulins, particularly during and after meals.In this work, we propose a strategy for the control of glycemia in presence of perturbations (meals), using injectable insulin preparations with fast and very fast absorption kinetics, particularly in the context of MDI diabetes therapy. The control method is validated in-silico, also with a comparison between the use of fast and ultra-fast insulin, while robustness is tested with respect to non-idealities including meal glucose content uncertainties, and quantized glycemia measurements and insulin doses.Preliminary results show the effectiveness of the approach taken and are promising in view of the application of the proposed techniques in more realistic experimental conditions.